-+ 0.00%
-+ 0.00%
-+ 0.00%

Fate Therapeutics presents Phase 1 data for off-the-shelf CAR-T FT819 in systemic lupus erythematosus at CCR-West 2026

PUBT·09/09/2026 11:06:10
Listen to the news
Fate Therapeutics presents Phase 1 data for off-the-shelf CAR-T FT819 in systemic lupus erythematosus at CCR-West 2026
  • Fate Therapeutics set an encore clinical data presentation on FT819 at the CCR – West meeting on Sept. 18, 2026.
  • Results were previously generated in an ongoing Phase 1 trial in systemic lupus erythematosus, with a May 14, 2026 data cutoff.
  • Data showed a favorable safety profile in the treated group, supporting use with reduced conditioning and potential same-day discharge.
  • Clinical activity was observed early, then maintained, reinforcing the rationale for the RECLAIM-LN Phase 2 trial in lupus nephritis.
  • Fate also scheduled a preclinical FT839 presentation at the same session, positioning a dual-target CAR T approach for autoimmune disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090700PRIMZONEFULLFEED9823560) on September 09, 2026, and is solely responsible for the information contained therein.